Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halting (PDF) further development months after filing to run a phase 3 trial. The Big Pharma disclosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback